Brain inflammation in epilepsy: Experimental and clinical evidence

Epilepsia

Volumn 46, Issue 11, 2005, Pages 1724-1743

  Vezzani, Annamaria ^a   Granata, Tiziana ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Anticonvulsant; Autoimmune diseases; Blood brain barrier; Innate and adaptive immunity; Neurodegeneration; Seizures; Stress

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CASPASE INHIBITOR; CD31 ANTIGEN; CHEMOKINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; LIPOXYGENASE INHIBITOR; LYMPHOTOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENIDONE; STEROID; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; VASCULAR CELL ADHESION MOLECULE 1; ANTIINFLAMMATORY AGENT; AUTACOID;

ADAPTIVE IMMUNITY; ANTICONVULSANT ACTIVITY; ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN DEPTH STIMULATION; CELL DEATH; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; ENCEPHALITIS; EPILEPSY; EXTRAVASATION; FEBRILE CONVULSION; FEVER; HUMAN; INFECTION; INNATE IMMUNITY; LANDAU KLEFFNER SYNDROME; LENNOX GASTAUT SYNDROME; NATURAL KILLER CELL; NERVE CELL EXCITABILITY; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RASMUSSEN SYNDROME; REVIEW; SEIZURE; SHIGELLA DYSENTERIAE; STRESS; SYSTEMATIC REVIEW; TEMPORAL LOBE EPILEPSY; TH1 CELL; TH2 CELL; TONIC CLONIC SEIZURE; TUBEROUS SCLEROSIS; WEST SYNDROME; ANIMAL; CAPILLARY PERMEABILITY; DISEASE MODEL; ENDOTHELIUM CELL; IMMUNOLOGY; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CELL DEATH; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENCEPHALITIS; ENDOTHELIAL CELLS; EPILEPSY; HUMANS; INFLAMMATION MEDIATORS; NERVE DEGENERATION; SEIZURES;

EID: 33644625777     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.00298.x     Document Type: Review

References (190)

1. Becher B, Prat A, Antel JP. Brain-immune connection: immunoregulatory properties of CNS-resident cells. Glia 2000;29:293-304.
2. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002;3:216-27.
3. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003;3:569-81.
4. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80.
5. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav Immun 2003;17:13-9.
6. Laflamme N, Echchannaoui H, Landmann R, et al. Cooperation between Toll-like receptor 2 and 4 in the brain of mice challenged with cell wall components derived from gram-negative and gram-positive bacteria. Eur J Immunol 2003;33:1127-38.
7. Chakravarty S, Herkenham M. Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J Neurosci 2005;25:1788-96.
8. Rivest S, Lacroix S, Vallieres L, et al. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 2000;223:22-38.
9. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001;2:734-44.
10. Jankowsky JL, Patterson PH. The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobiol 2001;63:125-49.
11. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004;16:1-13.
12. Pachter JS, de Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 2003;62:593-604.
13. Zucker DK, Wooten GF, Lothman EW. Blood-brain barrier changes with kainic acid-induced limbic seizures. Exp Neurol 1983;79:422-33.
14. Krizanac-Bengez L, Mayberg MR, et al. The cerebral vasculature as a therapeutic target for neurological disorders and the role of shear stress in vascular homeostatis and pathophysiology. Neurol Res 2004;26:846-53.
15. Webb AA, Muir GD. The blood-brain barrier and its role in inflammation. J Vet Intern Med 2000;14:399-411.
16. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions: review. Histol Histopathol 2004;19:535-64.
17. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 2000;21:141-7.
18. Engelhardt B, Wolburg-Buchholz K, Wolburg H. Involvement of the choroid plexus in central nervous system inflammation. Microsc Res Tech 2001;52:112-29.
19. Williams K, Alvarez X, Lackner AA. Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia 2001;36:156-64.
20. Karman J, Ling C, Sandor M, et al. Dendritic cells in the initiation of immune responses against central nervous system-derived antigens. Immunol Lett 2004;92:107-15.
21. Calabrese VP, Gruemer HD, Tripathi HL, et al. Serum cortisol and cerebrospinal fluid beta-endorphins in status epilepticus: their possible relation to prognosis. Arch Neurol 1993;50:689-93.
22. Baram TZ, Hatalski CG. Neuropeptide-mediated excitability: a key triggering mechanism for seizure generation in the developing brain. Trends Neurosci 1998;21:471-6.
23. Elenkov IJ, Webster EL, Torpy DJ, et al. Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Ann N Y Acad Sci 1999;876:1-11.
24. Elenkov IJ, Chrousos GP. Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab 1999;10:359-68.
25. Stoll G, Jander S, Schroeter M. Cytokines in CNS disorders: neurotoxicity versus neuroprotection. J Neural Transm Suppl 2000;59:81-9.
26. Weninger SC, Yankner BA. Inflammation and Alzheimer disease: the good, the bad, and the ugly. Nat Med 2001;7:527-8.
27. Beattie EC, Stellwagen D, Morishita W, et al. Control of synaptic strength by glial TNFalpha. Science 2002;295:2282-5.
28. Viviani B, Bartesaghi S, Gardoni F, et al. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 2003;23:8692-700.
29. Wang CX, Shuaib A. Involvement of inflammatory cytokines in central nervous system injury. Prog Neurobiol 2002;67:161-72.
30. Wilde GJ, Pringle AK, Sundstrom LE, et al. Attenuation and augmentation of ischaemia-related neuronal death by tumour necrosis factor-alpha in vitro. Eur J Neurosci 2000;12:3863-70.
31. Cheng B, Christakos S, Mattson MP. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 1994;12:139-53.
32. Mattson MP, Cheng B, Baldwin SA, et al. Brain injury and tumor necrosis factors induce calbindin D-28k in astrocytes: evidence for a cytoprotective response. J Neurosci Res 1995;42:357-70.
33. Minami M, Kuraishi Y, Satoh M. Effects of kainic acid on messenger RNA levels of IL-1 beta, IL-6, TNF alpha and LIF in the rat brain. Biochem Biophys Res Commun 1991;176:593-98.
34. Minami M, Kuraishi Y, Yamaguchi T, et al. Convulsants induce interleukin-1 beta messenger RNA in rat brain. Biochem Biophys Res Commun 1990;171:832-7.
35. Oprica M, Eriksson C, Schultzberg M. Inflammatory mechanisms associated with brain damage induced by kainic acid with special reference to the interleukin-1 system. J Cell Mol Med 2003;7:127-40.
36. Gahring LC, White HS, Skradski SL, et al. Interleukin-1alpha in the brain is induced by audiogenic seizure. Neurobiol Dis 1997;3:263-9.
37. Turrin NP, Rivest S. Innate immune reaction in response to seizures: implications for the neuropathology associated with epilepsy. Neurobiol Dis 2004;16:321-34.
38. Plata-Salaman CR, Ilyin SE, Turrin NP, et al. Kindling modulates the IL-1beta system, TNF-alpha, TGF-beta1, and neuropeptide mRNAs in specific brain regions. Brain Res Mol Brain Res 2000;75:248-58.
39. Vezzani A, Conti M, DeLuigi A, et al. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 1999;19:5054-65.
40. De Simoni MG, Perego C, Ravizza T, et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci 2000;12:2623-33.
41. Dinkel K, MacPherson A, Sapolsky RM. Novel glucocorticoid effects on acute inflammation in the CNS. J Neurochem 2003;84:705-16.
42. Vezzani A, Moneta D, Conti M, et al. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci U S A 2000;97:11534-9.
43. Dinarello CA. Proinflammatory cytokines. Chest 2000;118:503-8.
44. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
45. Srinivasan D, Yen JH, Joseph DJ, et al. Cell type-specific interleukin-1beta signaling in the CNS. J Neurosci 2004;24:6482-8.
46. Ravizza T, Vezzani A. Status epilepticus induces time-dependent neuronal and estrocytic expression of IL-1 receptor type-I in the rat limbic system. Neurosci (in press).
47. Balosso S, Ravizza T, Perego C, et al. Tumor necrosis factor-alpha inhibits seizures in mice via p75 receptors. Ann Neurol 2005;57:804-12.
48. Bernardino L, Xapelli S, Silva AP, et al. Modulator effects of interleukin 1beta and tumor necrosis factor-alpha on AMPA-induced excitotoxicity in mouse organotypic hippocampal slice cultures. J Neurosci 2005;25:6734-44.
49. MacEwan DJ. TNF ligands and receptors: a matter of life and death. Br J Pharmacol 2002;135:855-75.
50. Shinoda S, Skradski SL, Araki T, et al. Formation of a tumour necrosis factor receptor 1 molecular scaffolding complex and activation of apoptosis signal-regulating kinase 1 during seizure-induced neuronal death. Eur J Neurosci 2003;17:2065-76.
51. Lehtimaki KA, Peltola J, Koskikallio E, et al. Expression of cytokines and cytokine receptors in the rat brain after kainic acid-induced seizures. Brain Res Mol Brain Res 2003;110:253-60.
52. Naffah-Mazzacoratti MG, Bellissimo MI, Cavalheiro EA. Profile of prostaglandin levels in the rat hippocampus in pilocarpine model of epilepsy. Neurochem Int 1995;27:461-6.
53. Vezzani A, Moneta D, Richichi C, et al. Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. Epilepsia 2002;43(suppl 5):30-5.
54. Ravizza T, Balosso S, Lucas SM, et al. Pharmacological inhibition of caspase-1 or p38 MAP kinase phosphorylation potently inhibit seizures in rodents. Prog#906.17 San Diego: Socety of Neuroscience, 2004.
55. Sayyah M, Beheshti S, Shokrgozar MA, et al. Antiepileptogenic and anticonvulsant activity of interleukin-1 beta in amygdala-kindled rats. Exp Neurol 2005;191:145-53.
56. Schneider H, Pitossi F, Balschun D, et al. A neuromodulatory role of interleukin-1beta in the hippocampus. Proc Natl Acad Sci U S A 1998;95:7778-83.
57. Cunningham AJ, Murray CA, O'Neill LA, et al. Interleukin-1 beta (IL-1 beta) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. Neurosci Lett 1996;203:17-20.
58. Probert L, Akassoglou K, Pasparakis M, et al. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci U S A 1995;92:11294-8.
59. Dube C, Vezzani A, Behrens M, et al. Interleukin-1beta contributes to the generation of experimental febrile seizures. Ann Neurol 2005;57:152-5.
60. Heida JG, Boisse L, Pittman QJ. Lipopolysaccharide-induced febrile convulsions in the rat: short-term sequelae. Epilepsia 2004;45:1317-29.
61. Yuhas Y, Shulman L, Weizman A, et al. Involvement of tumor necrosis factor alpha and interleukin-1beta in enhancement of pentylenetetrazole-induced seizures caused by Shigella dysenteriae. Infect Immun 1999;67:1455-60.
62. Yuhas Y, Weizman A, Ashkenazi S. Bidirectional concentration-dependent effects of tumor necrosis factor alpha in Shigella dysenteriae-related seizures. Infect Immun 2003;71:2288-91.
63. Meli DN, Loeffler JM, Baumann P, et al. In pneumococcal meningitis, a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex. J Neuroimmunol 2004;151:6-11.
64. Clark IA, MacMicking JD, Gray KM, et al. Malaria mimicry with tumor necrosis factor: contrasts between species of murine malaria and Plasmodium falciparum. Am J Pathol 1992;140:325-36.
65. Stringer JL, Marks LM, White AC Jr, et al. Epileptogenic activity of granulomas associated with murine cysticercosis. Exp Neurol 2003;183:532-6.
66. Liu Z, Holmes GL. Basic fibroblast growth factor is highly neuroprotective against seizure-induced long-term behavioural deficits. Neuroscience 1997;76:1129-38.
67. Liu Z, Holmes GL. Basic fibroblast growth factor-induced seizures in rats. Neurosci Lett 1997;233:85-8.
68. Cuevas P, Gimenez-Gallego G. Antiepileptic effects of acidic fibroblast growth factor examined in kainic acid-mediated seizures in the rat. Neurosci Lett 1996;203:66-8.
69. De Sarro G, Rotiroti D, Audino MG, et al. Effects of interleukin-2 on various models of experimental epilepsy in DBA/2 mice. Neuroimmunomodulation 1994;1:361-9.
70. Nistico G, De Sarro G. Behavioral and electrocortical spectrum power effects after microinfusion of lymphokines in several areas of the rat brain. Ann N Y Acad Sci 1991;621:119-34.
71. Samland H, Huitron-Resendiz S, Masliah E, et al. Profound increase in sensitivity to glutamatergic but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J Neurosci Res 2003;73:176-87.
72. Campbell IL, Abraham CR, Masliah E, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A 1993;90:10061-5.
73. Sayyah M, Javad-Pour M, Ghazi-Khansari M. The bacterial endotoxin lipopolysaccharide enhances seizure susceptibility in mice: involvement of proinflammatory factors: nitric oxide and prostaglandins. Neuroscience 2003;122:1073-80.
74. Xiong ZQ, Qian W, Suzuki K, et al. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J Neurosci 2003;23:955-60.
75. Adams J, Collaco-Moraes Y, de Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 1996;66:6-13.
76. Ye ZC, Sontheimer H. Cytokine modulation of glial glutamate uptake: a possible involvement of nitric oxide. Neuroreport 1996;7:2181-5.
77. Kamikawa H, Hori T, Nakane H, et al. IL-1beta increases norepinephrine level in rat frontal cortex: involvement of prostanoids, NO, and glutamate. Am J Physiol 1998;275:R803-10.
78. Bezzi P, Domercq M, Brambilla L, et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001;4:702-10.
79. Zeise ML, Espinoza J, Morales P, et al. Interleukin-1beta does not increase synaptic inhibition in hippocampal CA3 pyramidal and dentate gyrus granule cells of the rat in vitro. Brain Res 1997;768:341-4.
80. Wang S, Cheng Q, Malik S, et al. Interleukin-1beta inhibits gamma-aminobutyric acid type A (GABA(A)) receptor current in cultured hippocampal neurons. J Pharmacol Exp Ther 2000;292:497-504.
81. Akassoglou K, Probert L, Kontogeorgos G, et al. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 1997;158:438-45.
82. Stellwagen D, Beattie EC, Seo JY, et al. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005;25:3219-28.
83. De Simoni MG, Imeri L. Cytokine-neurotransmitter interactions in the brain. Biol Signals Recept 1998;7:33-44.
84. Wallenstein MC. Attenuation of penicillin models of epilepsy by nonsteroidal anti-inflammatory drugs. Exp Neurol 1987;98:152-60.
85. Srivastava AK, Gupta YK. Aspirin modulates the anticonvulsant effect of diazepam and sodium valproate in pentylenetetrazole and maximal electroshock induced seizures in mice. Indian J Physiol Pharmacol 2001;45:475-80.
86. Kim HC, Jhoo WK, Bing G, et al. Phenidone prevents kainate-induced neurotoxicity via antioxidant mechanisms. Brain Res 2000;874:15-23.
87. Baik EJ, Kim EJ, Lee SH, et al. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res 1999;843:118-29.
88. Kunz T, Oliw EH. Nimesulide aggravates kainic acid-induced seizures in the rat. Pharmacol Toxicol 2001;88:271-6.
89. Paoletti AM, Piccirilli S, Costa N, et al. Systemic administration of N omega-nitro-L-arginine methyl ester and indomethacin reduces the elevation of brain PGE2 content and prevents seizures and hippocampal damage evoked by LiCl and tacrine in rat. Exp Neurol 1998;149:349-55.
90. Steinhauer HB, Hertting G. Lowering of the convulsive threshold by non-steroidal anti-inflammatory drugs. Eur J Pharmacol 1981;69:199-203.
91. Akarsu ES, Mamuk S, Comert A. Inhibition of pentylenetetrazol-induced seizures in rats by prostaglandin D2. Epilepsy Res 1998;30:63-8.
92. Forstermann U, Heldt R, Knappen F, et al. Potential anticonvulsive properties of endogenous prostaglandins formed in mouse brain. Brain Res 1982;240:303-10.
93. Moreno-Sanchez R, Bravo C, et al. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol 1999;57:743-52.
94. O'Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999;13:45-82.
95. Bough K, Benveniste M, Wilhem J, et al. Cyclooxygenase inhibition after pilocarpine-induced status epilepticus. Prog# 679.11. San Diego: Society of Neuroscience, 2004.
96. Kelley KA, Ho L, Winger D, et al. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol 1999;155:995-1004.
97. Nadeau S, Rivest S. Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J Neurosci 2003;23:5536-44.
98. Sapolsky RM. A mechanism for glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults. J Neurosci 1985;5:1228-32.
99. Roberts AJ, Keith LD. Sensitivity of the circadian rhythm of kainic acid-induced convulsion susceptibility to manipulations of corticosterone levels and mineralocorticoid receptor binding. Neuropharmacology 1994;33:1087-93.
100. Lee PH, Grimes L, Hong JS. Glucocorticoids potentiate kainic acid-induced seizures and wet dog shakes. Brain Res 1989;480:322-5.
101. Hirayama H, Kurimoto T, Wada S, et al. Antiepileptic effects of globulin-N, an intact human immunoglobulin and its tissue-distribution in kindled cats. Int J Clin Pharmacol Ther Toxicol 1986;24:109-22.
102. Ichiyama T, Ueno Y, Hasegawa M, et al. Intravenous immunoglobulin inhibits NF-kappaB activation and affects Fcgamma receptor expression in monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol 2004;369:428-33.
103. Ichiyama T, Ueno Y, Isumi H, et al. An immunoglobulin agent (IVIG) inhibits NF-kappaB activation in cultured endothelial cells of coronary arteries in vitro. Inflamm Res 2004;53:253-6.
104. Hulkkonen J, Koskikallio E, Rainesalo S, et al. The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among therapy resistant epilepsy patients. Epilepsy Res 2004;59:199-205.
105. Peltola J, Palmio J, Korhonen L, et al. Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epilepsy Res 2000;41:205-11.
106. Peltola J, Hurme M, Miettinen A, et al. Elevated levels of interleukin-6 may occur in cerebrospinal fluid from patients with recent epileptic seizures. Epilepsy Res 1998;31:129-33.
107. Peltola J, Laaksonen J, Haapala AM, et al. Indicators of inflammation after recent tonic-clonic epileptic seizures correlate with plasma interleukin-6 levels. Seizure 2002;11:44-6.
108. Pacifici R, Paris L, Di Carlo S, et al. Cytokine production in blood mononuclear cells from epileptic patients. Epilepsia 1995;36:384-7.
109. Sheng JG, Boop FA, Mrak RE, et al. Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1 alpha immunoreactivity. J Neurochem 1994;63:1872-9.
110. Crespel A, Coubes P, Rousset MC, et al. Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. Brain Res 2002;952:159-69.
111. Maldonado M, Baybis M, Newman D, et al. Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol Dis 2003;14:279-90.
112. Ravizza TRS, Spliet WGM, van Rijen PC, et al. Expression and cellular distribution of IL-1beta and IL-1Ra in focal cortical dysplasia and glioneuronal tumors. Washington, DC: 59th Annual Meeting AES, 2005.
113. Baranzini SE, Laxer K, Bollen A, et al. Gene expression analysis reveals altered brain transcription of glutamate receptors and inflammatory genes in a patient with chronic focal (Rasmussen's) encephalitis. J Neuroimmunol 2002;128:9-15.
114. Pociot F, Molvig J, Wogensen L, et al. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992;22:396-402.
115. Peltola J, Keranen T, Rainesalo S, et al. Polymorphism of the interleukin-1 gene complex in localization-related epilepsy. Ann Neurol 2001;50:275-6.
116. Heils A, Haug K, Kunz WS, et al. Interleukin-1beta gene polymorphism and susceptibility to temporal lobe epilepsy with hippocampal sclerosis. Ann Neurol 2000;48:948-50.
117. Buono RJ, Ferraro TN, O'Connor MJ, et al. Lack of association between an interleukin 1 beta (IL-1beta) gene variation and refractory temporal lobe epilepsy. Epilepsia 2001;42:782-4.
118. Gallagher BB, Flanigin HF, King DW, et al. The effect of electrical stimulation of medial temporal lobe structures in epileptic patients upon ACTH, prolactin, and growth hormone. Neurology 1987;37:299-303.
119. Galimberti CA, Magri F, Copello F, et al. Seizure frequency and cortisol and dehydroepiandrosterone sulfate (DHEAS) levels in women with epilepsy receiving antiepileptic drug treatment. Epilepsia 2005;46:517-23.
120. Baram TZ. Pathophysiology of massive infantile spasms: perspective on the putative role of the brain adrenal axis. Ann Neurol 1993;33:231-6.
121. Cornford EM. Epilepsy and the blood brain barrier: endothelial cell responses to seizures. Adv Neurol 1999;79:845-62.
122. Lansberg MG, O'Brien MW, Norbash AM, et al. MRI abnormalities associated with partial status epilepticus. Neurology 1999;52:1021-7.
123. Amato C, Elia M, Musumeci SA, et al. Transient MRI abnormalities associated with partial status epilepticus: a case report. Eur J Radiol 2001;38:50-4.
124. Paladin F, Bonazza A, Mameli R, et al. Cryptogenic temporal lobe epilepsy. semi-quantitative interictal 99mTc HMPAO SPECT: statistical correlation with clinical data and EEG. Ital J Neurol Sci 1999;20:237-42.
125. Pavlovsky L, Seiffert E, Heinemann U, et al. Persistent BBB disruption may underlie alpha interferon-induced seizures. J Neurol 2005;252:42-6.
126. Siemes HSM, Aksu F, Emrich R, et al. CSF protein profile in infantile spasms: influence of etiology and ACTH or dexamethasone treatment. Epilepsia 1984;25:368-76.
127. Devinsky O, Nadi S, Theodore WH, et al. Pleocytosis following simple, complex partial, and generalized tonic-clonic seizures. Ann Neurol 1988;23:402-3.
128. Tomkins O, Kaufer D, Korn A, et al. Frequent blood-brain barrier disruption in the human cerebral cortex. Cell Mol Neurobiol 2001;21:675-91.
129. van Engelen BG, Renier WO, Weemaes CM, et al. High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome; an add-on study. Eur J Pediatr 1994;153:762-9.
130. Wong M, Schlaggar BL, Landt M. Postictal cerebrospinal fluid abnormalities in children. J Pediatr 2001;138:373-7.
131. Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 2005;128:454-71.
132. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005;46:224-35.
133. Rasmussem T, Olsewski J, Lloyd-Smith D. Focal seizures due to chronic localized encephalitis. Neurology 1958;8:435-45.
134. Robitaille Y. Neuropathological aspects of chronic encephalitis. Boston: Butterworth-Heinemann, 1991.
135. Granata T, Fusco L, Gobbi G, et al. Experience with immunomodulatory treatments in Rasmussen's encephalitis. Neurology 2003;61:1807-10.
136. Pardo CA, Vining EP, Guo L, et al. The pathology of Rasmussen syndrome: stages of cortical involvement and neuropathological studies in 45 hemispherectomies. Epilepsia 2004;45:516-26.
137. Bauer J, Bien CG, Lassmann H. Rasmussen's encephalitis: a role for autoimmune cytotoxic T lymphocytes. Curr Opin Neurol 2002;15:197-200.
138. Neumann H, Medana IM, Bauer J, et al. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002;25:313-9.
139. Gahring L, Carlson NG, Meyer EL, et al. Granzyme B proteolysis of a neuronal glutamate receptor generates an autoantigen and is modulated by glycosylation. J Immunol 2001;166:1433-8.
140. Bien CG, Bauer J, Deckwerth TL, et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol 2002;51:311-8.
141. Rogers SW, Andrews PI, Gahring LC, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994;265:648-51.
142. Yang R, Puranam RS, Butler LS, et al. Autoimmunity to munc-18 in Rasmussen's encephalitis. Neuron 2000;28:375-83.
143. Wiendl H, Bien CG, Bernasconi P, et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 2001;57:1511-4.
144. Lang BWR, Bermudez I, Sattelle D, et al. Antibodies to alpha7 acetylcholine receptors in patients with Rasmussen's encephalitis. J Neuroimmunol 2004;154:192.
145. He XP, Patel M, Whitney KD, et al. Glutamate receptor GluR3 antibodies and death of cortical cells. Neuron 1998;20:153-63.
146. Twyman RE, Gahring LC, Spiess J, et al. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron 1995;14:755-62.
147. Antozzi C. Immunotherapy. Epilepsia 2004;45:20.
148. Pitkanen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 2002;1:173-81.
149. McLachlan RS, Levin S, Blume WT. Treatment of Rasmussen's syndrome with ganciclovir. Neurology 1996;47:925-8.
150. Fassbender K, Schneider S, Bertsch T, et al. Temporal profile of release of interleukin-1beta in neurotrauma. Neurosci Lett 2000;284:135-8.
151. Hart YM, Andermann F, Robitaille Y, et al. Double pathology in Rasmussen's syndrome: a window on the etiology? Neurology 1998;50:731-5.
152. Palmer CA, Geyer JD, Keating JM, et al. Rasmussen's encephalitis with concomitant cortical dysplasia: the role of GluR3. Epilepsia 1999;40:242-7.
153. Thom M, Moran NF, Plant GT, et al. Cortical dysplasia with angiodysgenesis and chronic inflammation in multifocal partial epilepsy. Neurology 1999;52:654-7.
154. Firlik KS, Adelson PD, Hamilton RL. Coexistence of a ganglioglioma and Rasmussen's encephalitis. Pediatr Neurosurg 1999;30:278-82.
155. Silver K, Andermann F, Meagher-Villemure K. Familial alternating epilepsia partialis continua with chronic encephalitis: another variant of Rasmussen syndrome? Arch Neurol 1998;55:733-6.
156. Coppola G, Plouin P, Chiron C, et al. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. Epilepsia 1995;36:1017-24.
157. Ishii K, Oguni H, Hayashi K, et al. Clinical study of catastrophic infantile epilepsy with focal seizures. Pediatr Neurol 2002;27:369-77.
158. Mantegazza R, Bernasconi P, Baggi F, et al. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 2002;131:179-85.
159. Yu Z, Zhou D, Bruce-Keller AJ, et al. Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury. J Neurosci 1999;19:8856-65.
160. Mattson MP, Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 2001;107:247-54.
161. Baulac S, Gourfinkel-An I, Nabbout R, et al. Fever, genes, and epilepsy. Lancet Neurol 2004;3:421-30.
162. Haveman J, Geerdink AG, Rodermond HM. Cytokine production after whole body and localized hyperthermia. Int J Hyperthermia 1996;12:791-800.
163. Virta M, Hurme M, Helminen M. Increased plasma levels of pro-and anti-inflammatory cytokines in patients with febrile seizures. Epilepsia 2002;43:920-3.
164. Tutuncuoglu S, Kutukculer N, Kepe L, et al. Proinflammatory cytokines, prostaglandins and zinc in febrile convulsions. Pediatr Int 2001;43:235-9.
165. Haspolat S, Mihci E, Coskun M, et al. Interleukin-1beta, tumor necrosis factor-alpha, and nitrite levels in febrile seizures. J Child Neurol 2002;17:749-51.
166. Lahat E, Livne M, Barr J, et al. Interleukin-1beta levels in serum and cerebrospinal fluid of children with febrile seizures. Pediatr Neurol 1997;17:34-6.
167. Ichiyama T, Nishikawa M, Yoshitomi T, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in cerebrospinal fluid from children with prolonged febrile seizures: comparison with acute encephalitis/encephalopathy. Neurology 1998;50:407-11.
168. Miceli Sopo S, Cuomo B, Federico G, et al. [In vivo and in vitro production of interleukin-1 after febrile convulsions]. Pediatr Med Chir 2001;23:83-7.
169. Virta M, Hurme M, Helminen M. Increased frequency of interleukin-1beta (-511) allele 2 in febrile seizures. Pediatr Neurol 2002;26:192-5.
170. Kanemoto K, Kawasaki J, Miyamoto T, et al. Interleukin (IL)1beta, IL-1alpha, and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy. Ann Neurol 2000;47:571-4.
171. Hulkkonen J, Laippala P, Hurme M. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Netw 2000;11:251-5.
172. Vargas DL, Nascimbene C, Krishnan C, et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005;57:67-81.
173. Hattori H. Spontaneous remission of spasms in West syndrome: implications of viral infection. Brain Dev 2001;23:705-7.
174. Liu ZS, Wang QW, Wang FL, et al. Serum cytokine levels are altered in patients with West syndrome. Brain Dev 2001;23:548-51.
175. Riikonen R. Infantile spasms: therapy and outcome. J Child Neurol 2004;19:401-4.
176. Dravet C, Natale O, Magaudda A, et al. Status epilepticus in the Lennox-Gastaut syndrome. Rev Electroencephalogr Neurophysiol Clin 1986;15:361-8.
177. Tassinari CA, Rubboli G, Volpi L, et al. Encephalopathy with electrical status epilepticus during slow sleep or ESES syndrome including the acquired aphasia. Clin Neurophysiol 2000;111(suppl 2):S94-102.
178. Hart YM, Cortez M, Andermann F, et al. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 1994;44:1030-6.
179. Kendall DA, McEwen BS, Enna SJ. The influence of ACTH and corticosterone on [3H]GABA receptor binding in rat brain. Brain Res 1982;236:365-74.
180. Pranzatelli MR. Putative neurotransmitter abnormalities in infantile spasms: cerebrospinal fluid neurochemistry and drug effects. J Child Neurol 1994;9:119-29.
181. Vidal C, Jordan W, Zieglgansberger W. Corticosterone reduces the excitability of hippocampal pyramidal cells in vitro. Brain Res 1986;383:54-9.
182. Snead OC 3rd. How does ACTH work against infantile spasms? Bedside to bench. Ann Neurol 2001;49:288-9.
183. Brunson KL, Eghbal-Ahmadi M, Bender R, et al. Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress. Proc Natl Acad Sci U S A 2001;98:8856-61.
184. Brunson KL, Avishai-Eliner S, Baram TZ. ACTH treatment of infantile spasms: mechanisms of its effects in modulation of neuronal excitability. Int Rev Neurobiol 2002;49:185-97.
185. Mikati MA, Saab R, Fayad MN, et al. Efficacy of intravenous immunoglobulin in Landau-Kleffner syndrome. Pediatr Neurol 2002;26:298-300.
186. Gross-Tsur V, Shalev RS, Kazir E, et al. Intravenous high-dose gamma globulins for intractable childhood epilepsy. Acta Neurol Scand 1993;88:204-9.
187. Ariizumi M, Baba K, Hibio S, et al. Immunoglobulin therapy in the West syndrome. Brain Dev 1987;9:422-5.
188. Ichiyama T, Okada K, Lipton JM, et al. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res 2000;857:246-51.
189. Matoth I, Pinto F, Sicsic C, et al. Inhibitory effect of carbamazepine on inflammatory mediators produced by stimulated glial cells. Neurosci Res 2000;38:209-12.
190. Seiffert E, Dreier P, Ivens S, et al. Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J Neurosci 2004;24:7829-36.